Advertisement

Picture Berlin Partner Life Sciences Report 2019/2020 Brandenburg 650x80px
Person › Details

Jonathan Stauber (ImaBiotech S.A.S.)

Stauber, Jonathan (ImaBiotech 201206 CEO)

 

Organisation Organisation ImaBiotech S.A.S.
  Group ImaBiotech (Group)
Products Product mass spectrometry services (MS services)
  Product 2 molecular imaging
     

ImaBiotech S.A.S.. (6/20/12). "Press Release: ImaBiotech Initiates a Long-term Collaboration with Genfit". Lille.

ImaBiotech and GENFIT (Alternext: ALGFT; ISIN: FR0004163111) today announce the initiation of a collaboration and the relocation of ImaBiotech to laboratories within GENFIT's headquarters. This long-term collaboration involves the sharing of technological platforms and mutual drug discovery services.

ImaBiotech has moved into this larger, more secure site to accommodate the most recent addition to their innovative platform, a unique imaging instrument (7 Tesla SolariX, Bruker Daltonics). Furthermore, the relocation enables the company to stay at the heart of the Parc Eurasanté, one of the largest European biopoles, and its extensive business and scientific network. Thanks to the laboratories and platforms made available by GENFIT, ImaBiotech will continue to develop its superior preclinical services to clients in France and around the world.

ImaBiotech, whose workforce has more than doubled in the past year, wished to seize this unique opportunity to support its development in the field of molecular analysis and to maintain the highest standards in quality.

"We are very excited about this opportunity to continue our steady growth by moving to the premises of a renowned French biotech company like GENFIT. This is also an opportunity to share and pool not only our resources, but also the 10 years of scientific and technical expertise of both companies," affirmed Jonathan Stauber, Chief Executive Officer of ImaBiotech.

Jean-François Mouney, Chairman and Chief Executive Officer of GENFIT, added: "This collaboration will provide ImaBiotech with access to the numerous pathophysiological models available at GENFIT, as well as our Drug Discovery expertise. For our part, we will be able to benefit from the advanced technologies developed by ImaBiotech, including mass spectrometry imaging, to accelerate our own programs."

The opening reception of ImaBiotech's new laboratories and the presentation of the collaboration with GENFIT will take place on June 27th - for further details of this event, follow the news on the website www.imabiotech.com.


About GENFIT:

GENFIT is a biopharmaceutical company focused on the Discovery and Development of drug candidates in therapeutic fields linked to cardiometabolic disorders (prediabetes/diabetes, atherosclerosis, dyslipidemia, inflammatory diseases…). GENFIT uses a multi-pronged approach based on early diagnosis, preventive solutions, and therapeutic treatments, and advances therapeutic research programs, either independently or in partnership with leading pharmaceutical companies, including Sanofi, to address these major public health concerns and their unmet medical needs. GENFIT's research programs have resulted in the creation of a rich and diversified pipeline of drug candidates at different stages of development, including GENFIT's lead proprietary compound, GFT505, that is currently in Phase II.

With facilities in Lille, France, and Cambridge, MA (USA), the Company has approximately 100 employees. GENFIT is a public company listed on the Alternext trading market by Euronext™ Paris (Alternext: ALGFT; ISIN: FR0004163111).
www.genfit.com


About ImaBiotech:

ImaBiotech accelerates the market launch of drugs and biocompounds in every therapeutic area with its unique imaging services and products. By increasing the precision and relevance of preclinical results, ImaBiotech supports biotechnology companies by reducing the attrition rate of their molecule development. ImaBiotech develops and proposes innovative molecular analysis services (detection, identification and quantification) via cutting-edge mass spectrometry imaging in the pharmaceutical and medical diagnostic field. Coupling this imaging expertise with standard approaches, ImaBiotech carries out specifically-adapted studies on the simultaneous biodistribution of several thousands of molecules (drugs and their metabolites, lipids, proteins, contrast agents, etc.), as well as biomarker identification/validation. www.imabiotech.com


Contacts

ImaBiotech:
Jonathan STAUBER, CEO
Tel : +33 9 7044 0008
www.imabiotech.com

GENFIT:
Jean-François Mouney, CEO & Chairman of the Management Board
Tel : +33 3 2016 4000

MILESTONES - Press Relations
Bruno Arabian
Tel : +33 1 75 44 87 40
Mobile : +33 6 87 88 47 26
barabian@milestones.fr

   
Record changed: 2020-08-13

Advertisement

Picture [iito] No Tracking 650x80px


More documents for Jonathan Stauber


To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to info@iito.de and simply fill the subject line with the word »MSC Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at Life-Sciences-Germany.com and Life-Sciences-Europe.com

Advertisement

Picture [iito] Männer Ballett 650x80px




» top